Please ensure Javascript is enabled for purposes of website accessibility

Here's Why argenx Stock Is Soaring Today

By Cory Renauer - May 26, 2020 at 12:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Positive pivotal trial results are giving investors a reason to cheer.

What happened

Shares of argenx (ARGX 1.32%), a clinical-stage biotechnology company, are on the move following positive results from the Adapt trial of efgartigimod. Investors excited about the future of argenx's lead candidate have pushed the stock 37.9% higher as of 12:38 p.m. EDT on Tuesday.

So what 

argenx doesn't have any products to sell at the moment, but results of the Adapt trial suggest efgartigimod could become a new treatment option for generalized myasthenia gravis (gMG) patients. An impressive 67.7% of those treated with efgartigimod achieved improvements on their myasthenia gravis activities of daily living (MG-ADL) scores of at least two points. Just 29.7% of patients given a placebo hit the same mark.

Folded dollar bill pointing up.

Image source: Getty Images.

Myasthenia gravis is a relatively rare immune disorder that weakens patients by jamming up the transmission of signals between their brains and their muscle fibers. If approved, annual sales of efgartigimod could reach $1 billion as a high-priced gMG treatment before the end of 2025.

Now what

The company plans to submit an application to treat gMG patients with efgartigimod by the end of 2020. If approved to treat this relatively limited population, though, it will run straight into competition with Soliris from Alexion Pharmaceuticals (ALXN).

Soliris earned approval to treat gMG with solid MG-ADL improvement results as well. The average patient treated with Soliris experienced a 4.2 point improvement on the 24-point MD-ADL scale compared to a 2.3 improvement among patients given a placebo. 

At recent prices, argenx is a $9.3 billion company without any products to sell. If investors begin worrying about the company's ability to launch efgartigimod into a competitive landscape, shares of this risky drugmaker could quickly tank.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

argenx SE Stock Quote
argenx SE
ARGX
$382.11 (1.32%) $4.98
Alexion Pharmaceuticals, Inc. Stock Quote
Alexion Pharmaceuticals, Inc.
ALXN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.